S. 164Advancing Education on Biosimilars Act of 2021

1 recorded action229 of these members are on the 2026 ballotWhat the measure does Read on Congress.gov

Sponsor: Margaret Wood Hassan [D-NH]
Cosponsors: 1 · 1 Republican
Policy area: Health
Committee: Health, Education, Labor, and Pensions Committee
Latest action: Apr 23, 2021 · Became Public Law No: 117-8.

IntroducedFeb 2, 2021
Passed the SenateMar 3, 2021
Passed the HouseApr 14, 2021
Sent to the PresidentApr 20, 2021
Became lawApr 23, 2021

What the measure doesCRS summary

Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

Written by the nonpartisan Congressional Research Service, describing S. 164 as public Law on Apr 23, 2021. It is not the text of the measure; a later amendment may have changed what it does.

How every member votedHouse roll call 101

House Apr 14, 2021

On Motion to Suspend the Rules and Pass

Advancing Education on Biosimilars Act

Passed · Two-thirds required

412 Yea 8 Nay 9 not voting

Crossed both parties 8 of 420 voting members broke with their own party: 8 Republicans.

Open the official roll call

How the chamber split

One dot per member. Select a seat or a bar to filter the list.

DemocratsRepublicansFilled: YeaRing: NayGrey: not voting or present

By party select a segment to filter

All members429 members

Democratic217 members

Republican212 members

marks half of the votes cast. A party’s majority is the side most of its voting members took.

Cosponsors1 · 1 Republican

Signing on is not a vote: a member can cosponsor S. 164 and vote against it. 1 signed when it was filed.

RBill Cassidy [R-LA]Original2026 profile

Who lobbied on S. 1649 organizations

Organizations that named S. 164 in a lobbying disclosure. Only those that cited the bill by number appear, so this is a floor, not a full list.

TEVA PHARMACEUTICALS USA INCfiled by TEVA PHARMACEUTICALS USA, INC.Its PAC: Teva Pharmaceuticals USA Inc. PAC

Health Issues11 filings · 3rd Quarter (July 1 - Sep 30) 2022Filing

GSK (FKA GLAXOSMITHKLINE INC.)

Copyright/Patent/Trademark · Health Issues · Budget/Appropriations · Medicare/Medicaid +1 more10 filings · 4th Quarter (Oct 1 - Dec 31) 2022Filing

COHERUS BIOSCIENCESfiled by RED+BLUE STRATEGIESIts PAC: Coherus Biosciences PAC

Pharmacy8 filings · 4th Quarter (Oct 1 - Dec 31) 2022Filing

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAIts PAC: Pharmaceutical Research & Manufacturers of America Better Government Committee

Budget/Appropriations · Copyright/Patent/Trademark · Health Issues · Medicare/Medicaid +1 more8 filings · 4th Quarter (Oct 1 - Dec 31) 2022Filing

NOVARTISIts PAC: Novartis Corp. PAC

Budget/Appropriations · Copyright/Patent/Trademark · Health Issues · Medicare/Medicaid +7 more5 filings · 2nd Quarter (Apr 1 - June 30) 2022Filing

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Health Issues · Medicare/Medicaid · Pharmacy3 filings · 3rd Quarter (July 1 - Sep 30) 2021Filing

COHERUS BIOSCIENCES, INC.filed by COHERUS BIOSCIENCESIts PAC: Coherus Biosciences PAC

Health Issues · Government Issues3 filings · 3rd Quarter (July 1 - Sep 30) 2021Filing

PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INCfiled by COVINGTON & BURLING LLPIts PAC: Pharmaceutical Research & Manufacturers of America Better Government Committee

Health Issues · Trade (domestic/foreign) · Copyright/Patent/Trademark2 filings · 2nd Quarter (Apr 1 - June 30) 2021Filing

THE BIOSIMILARS FORUMfiled by THORN RUN PARTNERSIts PAC: Biosimilars Forum PAC

Health Issues · Medicare/Medicaid2 filings · 2nd Quarter (Apr 1 - June 30) 2021Filing

52 disclosures name this measure. Retrieved from LDA.gov on 2026-10-04. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.